Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GB5121 |
Synonyms | |
Therapy Description |
GB5121 selectively inhibits BTK and is able to cross the blood-brain barrier, potentially leading to to reduced growth of BTK-overexpressing tumor cells (NCI Drug Dictionary; Cancer Res 2022;82(12_Suppl):Abstract nr 3330). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GB5121 | GB-5121|GB 5121 | BTK inhibitor 38 | GB5121 selectively inhibits BTK and is able to cross the blood-brain barrier, potentially leading to to reduced growth of BTK-overexpressing tumor cells (NCI Drug Dictionary; Cancer Res 2022;82(12_Suppl):Abstract nr 3330). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05242146 | Phase Ib/II | GB5121 | GB5121 in Adult Patients With Relapsed/Refractory CNS Lymphoma (STAR CNS) | Terminated | USA | NZL | ISR | FRA | CAN | AUS | 0 |